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Abstract
Anti-HBc positivity is a frequent cause of donation rejection at blood
banks. Hepatitis B virus (HBV) infection may also occur in HBsAg-
negative patients, a situation denoted occult infection. Similarly, very
low levels of HBV-DNA have also been found in the sera of patients
with chronic hepatitis C virus (HCV) infection, even in the absence of
serum HBsAg. Initially we searched for HBV-DNA in serum of 100
blood donors and 50 HCV-infected patients who were HBsAg nega-
tive/anti-HBc positive by nested-PCR and by an HBV monitor com-
mercial test for HBV-DNA. Anti-HBs seroconversion rates were
measured in 100 blood donors and in 22 patients with chronic HCV
infection after HBV vaccination to determine if the HBV vaccination
could eliminate an occult HBV infection in these individuals. Occult
HBV infection was detected in proportionally fewer blood donors (6/
100 = 6%) than chronic hepatitis C patients (12/50 = 24%) (P < 0.05).
We noted seroconversion in 6/6 (100%) HBV-DNA(+) and in 84/94
(89.4%) HBV-DNA(-) blood donors (P > 0.05). All subjects who were
HBV-DNA(+) before the first dose of HBV vaccine (D1), became
HBV-DNA(-) after D1, D2, and D3. Among 22 HCV-positive pa-
tients, 10 HBV-DNA(+) and 12 HBV-DNA(-), seroconversion was
observed in 9/10 (90%) HBV-DNA(+) and in 9/12 (75%) HBV-
DNA(-) subjects (P > 0.05). The disappearance of HBV-DNA in the
majority of vaccinated patients suggests that residual HBV can be
eliminated in patients with occult infection.
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Introduction
Infection with hepatitis B virus (HBV)
leads to a wide spectrum of clinical presenta-
tions, ranging from acute self-limited or,
rarely, fulminant hepatitis, to an asympto-
matic chronic carrier status, or chronic hepa-
titis with progression to cirrhosis. During
acute and chronic HBV infection, antibodies
against the core antigen of HBV (anti-HBc)
are found together with the surface antigen
of the virus (HBsAg), whereas resolved in-
fection is accompanied only by antibodies
against HBsAg (anti-HBs).
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Anti-HBc positivity is an important cause
of blood rejection at blood banks. Anti-HBc
screening continues to be necessary because,
in some cases, HBsAg negative/anti-HBc-
positive blood donors are able to transmit
HBV. In Northeast Brazil, the high preva-
lence of anti-HBc-positive blood donors has
resulted in a very high level of donation
rejection, with obvious consequences for
blood availability, generating very high costs
(1). As the sensitivity of polymerase chain
reaction (PCR) method has improved, indi-
viduals carrying HBV-DNA as the only
marker of infection have been detected more
often. In most parts of Europe and the United
States, 10-20% of all individuals with hepa-
titis B have anti-HBc as the only marker of
HBV infection (2). In about 10% of these
individuals HBV-DNA can be detected by
PCR (2,3). HBV infection may also occur in
HBsAg-negative patients who have sero-
logical markers of previous infection (anti-
HBs) (4). These HBV infections in patients
who lack detectable HBsAg are called oc-
cult infections (4), and their serum HBV-
DNA levels are usually less than 104 copies/
mL (5). Similarly, very low levels of HBV-
DNA have also been detected in the sera of
patients with chronic hepatitis C virus (HCV)
infection, even though there was no demon-
strable HBsAg in their serum (4,6-11).
We used PCR to determine the preva-
lence of occult HBV infection in serum
samples from 100 blood donors who were
HCV negative/HBsAg negative/anti-HBc
positive, with anti-HBc positive being the
only marker, and from 50 patients with
chronic HCV infection who were HBsAg
negative/anti-HBc positive, with anti-HBc
being the only marker. HBV-DNA was de-
tected in 6 and 24% of these patient groups,
respectively (12).
In the present investigation, we studied
the anti-HBs seroconversion rates in anti-
HBc-positive blood donors and in patients
with chronic HCV infection after HBV vac-
cination. We also examined the possibility
of eliminating an occult HBV infection with
HBV vaccination of these individuals.
Material and Methods
Patients
The study was conducted at the Hospital
das Clínicas, University of Campinas, Cam-
pinas, SP, Brazil, between 2000 and 2003,
after approval by the institutional Ethics
Committee. We selected 100 HBsAg-nega-
tive (Hepanostika Uniform II, Organon Tek-
nika, Boxtel, Netherlands) and anti-HBc-
positive (Hepanostika anti-HBc Uniform,
Organon Teknika) blood donors. All of these
blood donors were negative for HCV (HCV
MEIA Abbott/AxSYM, Chicago, IL, USA)
and HIV (anti-HIV 1.2.0, Murex, Dartfort,
UK) antibodies. These donors were retested
for HBsAg (AxSYM HBsAg, Abbott) and
anti-HBc (AxSYM Core, Abbott), and were
tested for anti-HBs (AxSYM AUSAB,
Abbott).
The study included also 50 HCV-RNA-
positive patients who were HBsAg negative/
anti-HBc positive/anti-HBs negative.
Vaccination protocol
All 100 blood donors and 22 HCV pa-
tients, who were anti-HBc positive alone,
gave written informed consent to take hepa-
titis B recombinant vaccine (Engerix B®;
group 1). A blood sample was taken 30 days
after the first dose of the vaccine (D1) to
quantify anti-HBs antibodies. Individuals
who seroconverted (anti-HBs >10 mIU/mL)
after D1 did not receive additional doses of
the vaccine. Patients without seroconver-
sion after D1 received a second dose of
vaccine (D2), and a blood sample was col-
lected 30 days later to evaluate anti-HBs
seroconversion. In cases without serocon-
version after D2, a third dose of vaccine
(D3) was given 5 months after D2, and a
blood sample was collected after 30 days to
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measure anti-HBs levels. Before the admin-
istration of each dose of HBV vaccine, a
serum sample was collected to check for
HBV-DNA by PCR in order to reveal an
occult HBV infection if present. All HBV-
DNA-positive blood donors and HCV-RNA-
positive patients received three doses of vac-
cine. Non-responders were individuals with
<10 mIU/mL anti-HBs after 3 doses of HBV
vaccine. All individuals who presented more
than 10 mIU/mL anti-HBs after three doses
were considered to be seroconverters (Fig-
ure 1).
Nested-PCR
The nested-PCR method for the detec-
tion of HBV-DNA in the 100 blood donors
and the 50 HCV-infected patients was per-
formed essentially as described by Kaneko
et al. (13). Carryover contamination was
prevented as described by Kwok et al. (14).
A 10-µL aliquot of serum was amplified in a
100-µL reaction volume containing 2.5 U
Taq polymerase (Bethesda Research Labo-
ratories, Life Technologies Inc., Gaithers-
burg, MD, USA), 200 µmol each of the four
deoxyribonucleic triphosphates, 1 µmol of
the primer pair (primers 1763 5'-GCTTT
GGGGCATGGACATTGACCCGTATAA-
3' and 2032R 5'CTGACTACTAATTCCC
TGGATGCTGGGTCT-3'), 50 mM KCl, 10
mM Tris-HCl, pH 8.3, and 1.5 mM MgCl2.
For reamplification of the samples, a 10-µL
aliquot of the primary PCR was amplified
using a primer pair (1778-E 5'-GACGAA
TTCCATTGACCCGTATAAAGAATT-3'
and 2017R-B 5'-ATGGGATCCCTGGAT
GCTGGGTCTTCCAAA-3'). Water was
used as a negative control. Serum from an
individual who was HBV positive by EIA,
and quantified by an Amplicor HBV Moni-
tor test (Roche Diagnostic Systems, Branch-
burg, NJ, USA), was used as a positive con-
trol. Serial dilutions were made with HBsAg
low-titer performance panel (PHA 105; Bos-
ton Biomedica, Inc., Boston, MA, USA),
which made it possible to establish a limit of
detection by PCR of 102 copies/mL. Samples
considered to be positive by PCR “in house”
were subsequently subjected to a commer-
cial test for HBV-DNA (HBV Monitor;
Roche) with a higher detection limit of 1,000
copies/mL.
Statistical analysis
Fisher’s exact test and the chi-square
test, when applicable, were used to compare
proportions. All P values were two-tailed,
and a P value <0.05 was considered to be
significant. Samples were considered to be
positive if they yielded at least two positive
results after three amplifications, and were
considered to be negative when they yielded
two negative results in two independent re-
actions.
Results
Occult infection with HBV was signifi-
cantly less frequent among blood donors (6/
100 = 6%) than among HCV-infected pa-
tients (12/50 = 24%; P < 0.05).
Figure 2 is a schematic representation of
the anti-HBs seroconversion and the rates of
elimination of HBV-DNA in the blood do-
nors and HCV-infected patients. After D1,
Figure 1. Vaccine procedures and resulting anti-HBs seroconversion.
N = 100
Blood donors HCV-RNA(-)
HBsAg(-)/anti-HBcAg(+)
N = 22
Patients HCV-RNA(+)
HBsAg(-)/anti-HBcAg(+)
HBV-DNA
(PCR)
HBV-DNA (PCR)
Seroconversion
Seroconversion
Non-seroconversion
D3
After D1, D2, D3
Seroconversion
N = 18 (82%)
Non-seroconversion
N = 4 (18%)
Non-seroconversion
N = 10 (10%)
Seroconversion
N = 90 (90%)
Non-seroconversion
D2
D1
Stop
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seroconversion was observed in 3/6 (50%)
HBV-DNA(+) subjects and in 56/94 (59.6%)
HBV-DNA(-) (P > 0.05). After D2, serocon-
version was observed in 4/6 (66.7%) HBV-
DNA(+) subjects and in 79/94 (84%) HBV-
DNA(-) subjects (P > 0.05). After D3, cumu-
lative seroconversion was observed in 6/6
(100%) HBV-DNA(+) and in 84/94 (89.4%)
HBV-DNA(-) (P > 0.05). Only 10/94 (10.6%)
HBV-DNA(-) subjects did not seroconvert
after three doses of vaccine. All HBV-
DNA(+) subjects in group 1 before D1 be-
came HBV-DNA(-) after D1, D2 and D3.
Among the HCV-infected patients, 22
completed the vaccine schedule (10 HBV-
DNA-positive subjects and 12 HBV-DNA-
negative subjects). After D1, seroconver-
sion was observed in 5/10 (50%) HBV-
DNA(+) subjects and in 6/12 (50%) HBV-
DNA(-) individuals (P > 0.05). After D2, we
observed seroconversion in 7/10 (70%)
HBV-DNA(+) subjects and in 8/12 (66.7%)
HBV-DNA(-) subjects (P > 0.05). After D3,
we observed cumulative seroconversion in
9/10 (90%) HBV-DNA(+) and in 9/12 (75%)
HBV-DNA(-) (P > 0.05). Only 1/10 (10%)
HBV-DNA(+) and 3/12 (25%) HBV-DNA(-)
did not seroconvert after three doses of vac-
cine. Only 1/10 (10%) of the HBV-DNA(+)
subjects continued to be positive after three
doses of vaccine
As can be seen, among the blood donors,
10, 50, and 40% had <10 mIU/mL, 10-99
mIU/mL and >100 mIU/mL anti-HBs levels
after three doses of vaccine, respectively.
These rates were significantly different from
those found in HCV-infected patients, which
were 36, 27, and 36%, respectively (P <
0.05, Table 1).
Discussion
The serological response to HBV vac-
cine may help distinguish between the vari-
ous diagnostic possibilities associated with
an isolated anti-HBc pattern (15). It is known
that immune individuals show an early, high-
titer anti-HBs response after hepatitis B vac-
cinations (16,17), while this response is un-
usual in a non-immune group (18). Further-
more, those individuals with chronic hepati-
tis B infection are serologically unrespon-
sive to vaccination (19).
We initially observed occult HBV infec-
tion in 24% of the HCV-infected patients
who were anti-HBc reactive. This percent-
age is about four times higher than the preva-
lence otherwise encountered in blood do-
nors, which was 6% and could be due to the
fact that these blood donors constituted a
low risk population. In any case, negativity
for HBsAg by the ELISA test does not nec-
essarily mean absence of infection, which
can be detected by PCR due to its higher
sensitivity compared to an ELISA test. Pa-
tients infected with HBV, who are co-in-
Blood
donors
N = 100
HCV
patients
N = 50
94 (94%)
HBV-DNA(-)
6 (6%)
HBV-DNA(+)
12 (24%)
HBV-DNA(+)
P < 0.05
38 (76%)
HBV-DNA(-)
Vaccination
N = 12N = 10
D1 5/10 (50%)
D2 7/10 (70%)
D3 9/10 (90%)
HBV-DNA(-)
After D1 7/9 (77.8%)
2 8 87.5
3 9 10 90
After D 7/ ( %)
After D / ( %)
D1 56/94 (59.6%)
D2 79/94 (84%)
D3 84/94 (89.4%)
D1 3/6 (50%)
D2 4/6 (66.7%)
D3 6/6 (100%)
D1 6/12 (50%)
D2 8/12 (66.7%)
D3 9/12 (75%)
HBV-DNA(-)
100% after
D1/D2/D3
*
*
Figure 2. Anti-HBs seroconversion and HBV-DNA elimination after each HBV vaccination
dose. *P < 0.05, HCV patients compared to blood donors (Fisher’s test).
Table 1. Accumulated anti-HBs seroconversion in response to the vaccine after three
doses.
Anti-HBs Anti-HBc(+)/HCV(-) Anti-HBc(+)/HCV(+)
Group 1 (N = 100) Group 2 (N = 22)
<10 mIU/mL 10 (10%) 8 (36%)
10-99 mIU/mL 50 (50%) 6 (27%)
>100 mIU/mL 40 (40%) 8 (36%)
Data are reported as the number of patients and percentage in parentheses.
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fected with HCV, seem to have lower viral
replication activity, indicating mutual inter-
ference and suggesting that HCV has a sup-
pressive effect on HBV (20-24).
In a recent study, 33 blood donors repeti-
tively found to have anti-HBc alone were
vaccinated against HBV infection, and 13
(39%) showed seroconversion 30 days after
taking one dose of the HBV vaccine. The
other 20 patients received a second dose and
15 (75%) seroconverted. One of 5 patients
without anti-HBs seroconversion received a
third dose and finally seroconverted, with a
total seroconversion rate of 88% (29/33).
Next, 24 of 33 blood donors had their blood
tested for HBV-DNA by PCR several months
later and none was reactive (25). In another
study, 120 repeatedly reactive isolated anti-
HBc blood donors received a single dose of
HBV recombinant vaccine. An HBV-DNA
determination by PCR was carried out for
those who did not test positive for anti-HBs
after vaccination. Thirty-eight donors (34%)
showed seroconversion after a single dose of
HBV vaccine. Hepatitis DNA was not found
in any of the donors (26).
In our study, we vaccinated blood donors
and monitored their response to HBV vacci-
nation. We found that 59% responded to the
first vaccine dose, 83% had cumulative se-
roconversion after the second vaccine dose,
and 90% had cumulative seroconversion af-
ter the third vaccine dose. We also found no
significant difference between the serocon-
version rates of HBV-DNA-positive versus
-negative subjects. This response pattern led
us to postulate that these blood donors could
be immune to hepatitis B, having low levels
of antibodies, undetected by traditional meth-
ods. All of the patients who were HBV-DNA
positive before vaccination became nega-
tive after vaccination. This leads us to think
that the vaccine stimulus eliminated the re-
sidual HBV or reduced the viral load to the
point that it was no longer detectable by
PCR. On this basis, we propose that a small
quantity of HBV, with residual replication
rates, would be incapable of stimulating the
immune system and producing high levels
of anti-HBs. Inoculation with a vaccine made
with HBV surface antigens could have pro-
voked this stimulation and consequently in-
creased the production of anti-HBs.
Stimulating the appearance or the reap-
pearance of anti-HBsAg by vaccination is a
way of checking for the development of
immunity against HBV and the possible
elimination of the infectious agent (25). This
could be a means of reducing the transmis-
sion of HBV in endemic regions and could
also make a rejected donor acceptable, re-
ducing the blood supply problem. The elimi-
nation of HBV-DNA demonstrated by our
relatively sensitive PCR “in house” test (100
copies/mL) indicates that we may have suc-
ceeded in eliminating residual HBV in pa-
tients with occult infection. In the studies
cited above, HBV-DNA was only tested af-
ter vaccination. Additional research should
be done to confirm and extend our conclu-
sion that vaccination with seroconversion of
anti-HBs is able to eliminate HBV-DNA in
patients with occult HBV infection.
Hepatitis B vaccination is recommended
for patients with chronic HCV infection (27).
Among HCV-infected patients without HBV
infection, the main objective is to protect
them against HBV infection. In the present
study, among anti-HBc reactive patients, with
or without hepatitis C, we observed serocon-
version rates of 82 and 90%, respectively.
This indicates that patients co-infected or
not with HCV will seroconvert, independent
of the presence or absence of this infectious
agent. In other words, HCV did not inhibit
the production of anti-HBs in hepatitis C
patients who already had anti-HBc anti-
bodies. In this anti-HBc reactive/HCV-posi-
tive group, the presence or absence of HBV-
DNA had no significant effect on the sero-
conversion rate, as was also found in the
blood donor group. We also analyzed elimi-
nation of HBV-DNA after vaccination.
Among the patients who had HBV-DNA,
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we observed elimination in 77.8, 87.5, and
90%, after D1, D2 and D3, respectively. All
samples positive for HBV-DNA by PCR “in
house” were negative for HBV-DNA when
assayed with an automatic commercial test.
This was not the same as we found for the
blood donors, 100% of whom seroconverted
after three doses of HBV vaccine. Among
the patients with HCV, vaccination was not
able to reduce or eliminate the virus in 10%
of cases. It is known that patients with hepa-
titis C, co-infected with HBV or HIV, had
lower rates of sustained response (elimina-
tion of the virus) when treated with interfer-
on, possibly as a consequence of interac-
tions between these viruses. It is also known
that there is less seroconversion to anti-HBs
in patients with HCV who are vaccinated
against HBV (27).
We did not find a significant difference
in the percentage of seroconversion to anti-
HBs between groups with or without HBV-
DNA. However, when we compare the two
groups, we note that there are significantly
more non-responders among the HCV-posi-
tive patients than among those unaffected by
HCV.
Additional studies with hepatitis B vac-
cination are needed to determine its efficacy
to protect patients infected with hepatitis C,
and to see if it is feasible to eliminate re-
sidual HBV in previously infected patients.
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